Comparison of the action of cholecystokinin, carbachol and vasoactive intestinal peptide on receptor-activated formation of cyclic GMP and cyclic AMP in the striatum and the pancreas.

O'Shaughnessy C, Bhoola KD

Biochemical pharmacology1 Nov 1986Cited by 7 (Europe PMC)

PMID3022747DOI10.1016/0006-2952(86)90026-2PepBankPUB-03022747

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In rat striatal slices and guinea-pig pancreatic lobules, VIP significantly stimulated cyclic AMP formation.
In plain wordsIn lab tests on rat brain and guinea-pig pancreas tissue, VIP raised cyclic AMP levels.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseCyclic AMP formation
Study
rat and guinea pign: not reported in source
rat striatal slices and guinea-pig pancreatic lobules
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Vasoactive intestinal peptide (VIP) significantly stimulated the formation of cyclic AMP in both striatal and pancreatic tissue without effect on levels of cyclic GMP in these tissues.
Report a problemFND-0302274701
02LabEx vivo tissueMechanism
In rat striatal slices and guinea-pig pancreatic lobules, VIP had no effect on cyclic GMP levels.
In plain wordsIn lab tests on rat brain and guinea-pig pancreas tissue, VIP did not change cyclic GMP levels.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCyclic GMP formation
Study
rat and guinea pign: not reported in source
rat striatal slices and guinea-pig pancreatic lobules
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Vasoactive intestinal peptide (VIP) significantly stimulated the formation of cyclic AMP in both striatal and pancreatic tissue without effect on levels of cyclic GMP in these tissues.
Report a problemFND-0302274702

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In rat striatal slices, carbachol significantly inhibited the VIP-stimulated increase in cyclic AMP.
In plain wordsIn lab tests on rat brain tissue, carbachol reduced the cyclic AMP rise that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseVIP-stimulated cyclic AMP with carbachol
Study
ratn: not reported in source
rat striatal slices
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
In rat striatal slices carbachol significantly inhibited the VIP-stimulated increase in cyclic AMP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0302274703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.